Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents.

[1]  J. Bernstein,et al.  Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. , 2015, Immunotherapy.

[2]  J. Bernstein,et al.  Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. , 2015, The journal of allergy and clinical immunology. In practice.

[3]  J. Bernstein,et al.  Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  K. Beusterien,et al.  The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. , 2014, Allergy and asthma proceedings.

[5]  C. Hack,et al.  Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. , 2013, British journal of clinical pharmacology.

[6]  J. Sheikh,et al.  A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. , 2013, The Journal of allergy and clinical immunology.

[7]  T. Machnig,et al.  Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review. , 2013, Allergy and asthma proceedings.

[8]  R. Lockey,et al.  Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[9]  R. Ree,et al.  Immunosafety of Recombinant Human C1-Inhibitor in Hereditary Angioedema: Evaluation of IgE Antibodies , 2013, Clinical Drug Investigation.

[10]  J. Speight,et al.  Content Validity of Visual Analog Scales to Assess Symptom Severity of Acute Angioedema Attacks in Adults with Hereditary Angioedema , 2012, The Patient - Patient-Centered Outcomes Research.

[11]  M. Triggiani,et al.  Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension study , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  D. Meyer‐Olson,et al.  Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies , 2012, European Journal of Pediatrics.

[13]  C. Town,et al.  Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[15]  A. Sheffer,et al.  Ecallantide for the treatment of acute attacks in hereditary angioedema. , 2010, The New England journal of medicine.

[16]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.

[17]  H. Joller-jemelka,et al.  Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. , 2008, Journal of immunological methods.

[18]  J. Hagan,et al.  Acute pancreatitis due to hereditary angioedema. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[19]  K. Bork,et al.  Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.